Nasdaq

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease

LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23) In pre-specified subgroups of patients with moderate Alzheimer’s ...
Seeking Alpha

Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update

BOTHELL, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow ...
Seeking Alpha

Athira Pharma Announces Reverse Stock Split

BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow ...
Nasdaq

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative ...